Salvatore Michele Carnazzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Salvatore Michele Carnazzo has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Domenico Pratico
Unit of Pediatrics, Department of Medicine and Surgery, University Kore of Enna, Enna, Italy
5 shared publications Desirèe Balconara
Pediatric Unit, Department of Pediatrics Azienda Ospedaliero Universitaria Policlinico G. Rodolico–San Marco, University of Catania Catania Italy
5 shared publicationsGiuseppe Fabio Parisi
Pediatric Respiratory and Cystic Fibrosis Unit, San Marco Hospital, University of Catania, Department of Clinical and Experimental Medicine, Catania, Italy
3 shared publications- Marcello Maida
Kore University of Enna, Italy
3 shared publications Salvatore Leonardi
Pediatric Respiratory and Cystic Fibrosis Unit, San Marco Hospital, University of Catania, Department of Clinical and Experimental Medicine, Catania, Italy
3 shared publications- Alessandro Vitello
Department of Medicine and Surgery, University of Enna ‘Kore’, 94100 Enna, Italy
2 shared publications
Latest Publications
- Open Access
Early-Life Gut Microbiota and the Pediatric Gut–Lung Axis: A Systematic Review of Clinical, Preclinical, and Mechanistic Evidence
Background/Objectives: The early-life gut microbiota plays a pivotal role in immune maturation and may influence respiratory health through the gut–lung axis. However, evidence linking microbial development, dysbiosis, microbial metabolites, and microbiota-targeted interventions to pediatric respiratory outcomes remains heterogeneous. This systematic review aimed to synthesize clinical and preclinical evidence on the pediatric gut–lung axis and its underlying mechanisms. Methods: This systematic review followed PRISMA 2020 guidelines and a prospectively registered PROSPERO protocol (CRD420251062905). PubMed, Scopus, and Web of Science were searched for studies published from January 2014 to March 2025. Eligible primary studies included randomized controlled trials, observational studies, and mechanistically relevant animal models. Risk of bias was assessed using RoB 2, the Newcastle–Ottawa Scale, and SYRCLE’s tool, respectively. Reviews were examined separately to provide mechanistic and translational context without contributing to the primary evidence synthesis. Results: Twenty-five primary studies (11 clinical and 14 preclinical) were included in the systematic evidence synthesis, while 54 reviews provided complementary contextual evidence. Early gut and airway microbial communities showed substantial overlap after birth followed by progressive niche-specific divergence. Early-life dysbiosis, including depletion of beneficial taxa and expansion of potentially pathogenic bacteria, was associated with asthma, recurrent wheezing, respiratory infections, and neonatal lung injury. Short-chain fatty acids emerged as key mediators of gut–lung immune signaling. Clinical trials suggested potential respiratory and immunological benefits of probiotic and synbiotic interventions, while preclinical models supported mechanistic links involving intestinal barrier dysfunction, microbial metabolites, and inflammatory pathways. Conclusions: Current evidence supports a biologically plausible and clinically relevant pediatric gut–lung axis. However, methodological heterogeneity and the limited availability of longitudinal clinical studies warrant cautious interpretation and further well-designed research before microbiota-targeted strategies can be routinely translated into pediatric respiratory care.
Open AccessEarly-Life Gut Microbiota and the Pediatric Gut–Lung Axis: A Systematic Review of Clinical, Preclinical, and Mechanistic Evidence
Background/Objectives: The early-life gut microbiota plays a pivotal role in immune maturation and may influence respiratory health through the gut–lung axis. However, evidence linking microbial development, dysbiosis, microbial metabolites, and microbiota-targeted interventions to pediatric respiratory outcomes remains heterogeneous. This systematic review aimed to synthesize clinical and preclinical evidence on the pediatric gut–lung axis and its underlying mechanisms. Methods: This systematic review followed PRISMA 2020 guidelines and a prospectively registered PROSPERO protocol (CRD420251062905). PubMed, Scopus, and Web of Science were searched for studies published from January 2014 to March 2025. Eligible primary studies included randomized controlled trials, observational studies, and mechanistically relevant animal models. Risk of bias was assessed using RoB 2, the Newcastle–Ottawa Scale, and SYRCLE’s tool, respectively. Reviews were examined separately to provide mechanistic and translational context without contributing to the primary evidence synthesis. Results: Twenty-five primary studies (11 clinical and 14 preclinical) were included in the systematic evidence synthesis, while 54 reviews provided complementary contextual evidence. Early gut and airway microbial communities showed substantial overlap after birth followed by progressive niche-specific divergence. Early-life dysbiosis, including depletion of beneficial taxa and expansion of potentially pathogenic bacteria, was associated with asthma, recurrent wheezing, respiratory infections, and neonatal lung injury. Short-chain fatty acids emerged as key mediators of gut–lung immune signaling. Clinical trials suggested potential respiratory and immunological benefits of probiotic and synbiotic interventions, while preclinical models supported mechanistic links involving intestinal barrier dysfunction, microbial metabolites, and inflammatory pathways. Conclusions: Current evidence supports a biologically plausible and clinically relevant pediatric gut–lung axis. However, methodological heterogeneity and the limited availability of longitudinal clinical studies warrant cautious interpretation and further well-designed research before microbiota-targeted strategies can be routinely translated into pediatric respiratory care.
- Open Access
- 8 July 2026
- Published by Elsevier in SSRN Electronic Journal
Immunometabolic signatures of neonatal hypoxic–ischemic encephalopathy: metabolomic insights into pediatric neuroinflammation
Neonatal hypoxic–ischemic encephalopathy (HIE) remains a major cause of mortality and long-term neurodevelopmental impairment in term and near-term infants. Although traditionally considered a disorder of impaired cerebral oxygenation and energy failure, increasing evidence indicates that secondary brain injury in HIE is strongly influenced by neuroinflammatory and immunometabolic mechanisms. Metabolomics has emerged as a promising systems biology approach for characterizing the complex biochemical alterations associated with hypoxic–ischemic injury and for identifying translational biomarkers linked to disease severity and neurological outcome. This structured narrative review summarizes current evidence regarding metabolomic alterations in neonatal HIE, with particular focus on the interaction between mitochondrial dysfunction, oxidative stress, innate immune activation, and metabolic reprogramming. A systematic literature search was performed across PubMed/MEDLINE, Scopus, Web of Science, and Embase databases. Twenty-three studies investigating metabolomic profiles in neonatal HIE or perinatal asphyxia were included in the qualitative synthesis. Across studies, recurrent metabolomic abnormalities involved pathways related to anaerobic glycolysis, tricarboxylic acid cycle dysfunction, amino acid metabolism, lipid remodeling, oxidative stress, and kynurenine pathway activation. Elevated lactate, altered acylcarnitines, glutamate dysregulation, phospholipid abnormalities, and oxidative stress-associated metabolites were consistently associated with HIE severity, electroencephalographic abnormalities, magnetic resonance imaging-defined brain injury, and adverse neurodevelopmental outcomes. Emerging evidence further suggests that several metabolic intermediates may actively participate in inflammatory signaling and microglial activation, supporting the concept of HIE as a dynamic neuroimmunometabolic disorder rather than a purely hypoxic insult. Despite substantial methodological heterogeneity, current findings highlight the translational potential of metabolomic profiling for biomarker discovery, risk stratification, and development of targeted neuroprotective strategies. Improved integration of metabolomics with neuroimmunology and systems biology approaches may advance precision medicine in neonatal neurocritical care.
- 8 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImmunometabolic signatures of neonatal hypoxic–ischemic encephalopathy: metabolomic insights into pediatric neuroinflammation
Neonatal hypoxic–ischemic encephalopathy (HIE) remains a major cause of mortality and long-term neurodevelopmental impairment in term and near-term infants. Although traditionally considered a disorder of impaired cerebral oxygenation and energy failure, increasing evidence indicates that secondary brain injury in HIE is strongly influenced by neuroinflammatory and immunometabolic mechanisms. Metabolomics has emerged as a promising systems biology approach for characterizing the complex biochemical alterations associated with hypoxic–ischemic injury and for identifying translational biomarkers linked to disease severity and neurological outcome. This structured narrative review summarizes current evidence regarding metabolomic alterations in neonatal HIE, with particular focus on the interaction between mitochondrial dysfunction, oxidative stress, innate immune activation, and metabolic reprogramming. A systematic literature search was performed across PubMed/MEDLINE, Scopus, Web of Science, and Embase databases. Twenty-three studies investigating metabolomic profiles in neonatal HIE or perinatal asphyxia were included in the qualitative synthesis. Across studies, recurrent metabolomic abnormalities involved pathways related to anaerobic glycolysis, tricarboxylic acid cycle dysfunction, amino acid metabolism, lipid remodeling, oxidative stress, and kynurenine pathway activation. Elevated lactate, altered acylcarnitines, glutamate dysregulation, phospholipid abnormalities, and oxidative stress-associated metabolites were consistently associated with HIE severity, electroencephalographic abnormalities, magnetic resonance imaging-defined brain injury, and adverse neurodevelopmental outcomes. Emerging evidence further suggests that several metabolic intermediates may actively participate in inflammatory signaling and microglial activation, supporting the concept of HIE as a dynamic neuroimmunometabolic disorder rather than a purely hypoxic insult. Despite substantial methodological heterogeneity, current findings highlight the translational potential of metabolomic profiling for biomarker discovery, risk stratification, and development of targeted neuroprotective strategies. Improved integration of metabolomics with neuroimmunology and systems biology approaches may advance precision medicine in neonatal neurocritical care.
- Open Access
Strain-Specific Effects of Early-Life Probiotic Supplementation on Respiratory Infections in Infants: A Systematic Review and Meta-Analysis
Background/Objectives: Probiotic and synbiotic supplementation has been proposed as a preventive strategy against respiratory tract infections (RTIs) in early childhood, although evidence in infants and young children remains inconsistent. This systematic review and meta-analysis aimed to evaluate the effects of probiotic or synbiotic supplementation administered during the first 24 months of life on respiratory infection outcomes. Methods: PubMed/MEDLINE, Embase, and Scopus were systematically searched for randomized controlled trials published between January 2015 and 30 September 2025. Eligible studies included infants and children aged ≤24 months receiving oral probiotics or synbiotics compared with placebo, no intervention, or standard care. The primary outcome was the incidence of at least one upper respiratory tract infection (URTI), while the secondary outcome was the incidence of any RTI. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using random-effects models. Risk of bias was assessed using the Cochrane RoB 2 tool, and certainty of evidence was evaluated according to the GRADE approach. Results: Nine randomized controlled trials were included. Probiotic or synbiotic supplementation did not significantly reduce the risk of URTI (OR 0.95, 95% CI 0.47–1.95; I2 = 78%). A non-significant trend toward a reduced risk of any RTI was observed (OR 0.66, 95% CI 0.35–1.25; I2 = 69%). Exploratory subgroup analyses suggested possible strain-specific effects, with signals observed for Bifidobacterium longum subsp. infantis in relation to URTI prevention and Lactiplantibacillus plantarum ATCC 202195 for reduction in any RTI. However, these findings were based on a limited number of studies and should be interpreted cautiously. No serious adverse events attributable to supplementation were reported. Conclusions: Current evidence does not support the routine use of probiotic or synbiotic supplementation for the prevention of respiratory infections in children aged ≤24 months. However, potential strain-specific benefits warrant further investigation in adequately powered randomized trials.
Open AccessStrain-Specific Effects of Early-Life Probiotic Supplementation on Respiratory Infections in Infants: A Systematic Review and Meta-Analysis
Background/Objectives: Probiotic and synbiotic supplementation has been proposed as a preventive strategy against respiratory tract infections (RTIs) in early childhood, although evidence in infants and young children remains inconsistent. This systematic review and meta-analysis aimed to evaluate the effects of probiotic or synbiotic supplementation administered during the first 24 months of life on respiratory infection outcomes. Methods: PubMed/MEDLINE, Embase, and Scopus were systematically searched for randomized controlled trials published between January 2015 and 30 September 2025. Eligible studies included infants and children aged ≤24 months receiving oral probiotics or synbiotics compared with placebo, no intervention, or standard care. The primary outcome was the incidence of at least one upper respiratory tract infection (URTI), while the secondary outcome was the incidence of any RTI. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using random-effects models. Risk of bias was assessed using the Cochrane RoB 2 tool, and certainty of evidence was evaluated according to the GRADE approach. Results: Nine randomized controlled trials were included. Probiotic or synbiotic supplementation did not significantly reduce the risk of URTI (OR 0.95, 95% CI 0.47–1.95; I2 = 78%). A non-significant trend toward a reduced risk of any RTI was observed (OR 0.66, 95% CI 0.35–1.25; I2 = 69%). Exploratory subgroup analyses suggested possible strain-specific effects, with signals observed for Bifidobacterium longum subsp. infantis in relation to URTI prevention and Lactiplantibacillus plantarum ATCC 202195 for reduction in any RTI. However, these findings were based on a limited number of studies and should be interpreted cautiously. No serious adverse events attributable to supplementation were reported. Conclusions: Current evidence does not support the routine use of probiotic or synbiotic supplementation for the prevention of respiratory infections in children aged ≤24 months. However, potential strain-specific benefits warrant further investigation in adequately powered randomized trials.
- Open Access
- 18 June 2026
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 419, 579005
Probiotic, prebiotic, and synbiotic interventions targeting the early-life gut–brain axis: A systematic review of randomized controlled trials
- 18 June 2026
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 419, 579005
Open AccessProbiotic, prebiotic, and synbiotic interventions targeting the early-life gut–brain axis: A systematic review of randomized controlled trials
- 15 June 2026
- Published by Wiley in Journal of Paediatrics and Child Health
Artificial Intelligence in Neonatal Hip Ultrasound: A Scoping Review of Methods and Clinical Evidence
Background: Developmental dysplasia of the hip (DDH) is among the most common musculoskeletal disorders in infants. Ultrasound, especially the Graf method, is the gold standard for early diagnosis but suffers from operator dependence and variability. Artificial intelligence (AI) and machine learning (ML) have recently been applied to improve acquisition, measurement, and classification tasks in neonatal hip ultrasound. Objective: To systematically map and synthesise the literature on AI/ML applications for neonatal hip ultrasound, identifying algorithmic approaches, tasks, study characteristics, performance metrics, and knowledge gaps. Methods: A scoping review was conducted using the Arksey and O’Malley framework, refined by the Joanna Briggs Institute, and reported according to PRISMA‐ScR. The protocol was registered in PROSPERO (CRD420251150044). The protocol was initially registered as a systematic review and subsequently conducted as a scoping review; this methodological adaptation is acknowledged. PubMed/MEDLINE, Embase, Scopus, and IEEE Xplore were searched for English‐language studies from January 1, 2015, to September 10, 2025. Eligible studies evaluated AI/ML algorithms for neonatal hip ultrasound in infants ≤ 12 months. Results: From 192 records, 41 studies met inclusion criteria. Publications increased from 2020 onward, with China and Canada contributing over half. Most were retrospective, single‐centre developments using convolutional neural networks; a minority used YOLO detectors or transformer models. Tasks included landmark detection/segmentation (53.7%), automated α / β angle estimation (26.8%), classification (19.5%), and scan quality assessment (≈10%). Because some studies addressed multiple analytic tasks, these categories were not mutually exclusive and percentages therefore exceed 100%. Internal performance was high (ICC up to 0.94, Dice > 0.90, AUC ≥ 0.95), but external validation was rare (≈5%). Conclusion: AI/ML has been applied to neonatal hip ultrasound primarily for landmark detection, angle estimation, classification, and scan‐quality assessment. Reported internal performance is often high; however, clinically relevant diagnostic accuracy studies remain limited, external validation is rare, and most evidence derives from single‐centre datasets. These limitations currently constrain clinical generalizability.
- 15 June 2026
- Published by Wiley in Journal of Paediatrics and Child Health
Artificial Intelligence in Neonatal Hip Ultrasound: A Scoping Review of Methods and Clinical Evidence
Background: Developmental dysplasia of the hip (DDH) is among the most common musculoskeletal disorders in infants. Ultrasound, especially the Graf method, is the gold standard for early diagnosis but suffers from operator dependence and variability. Artificial intelligence (AI) and machine learning (ML) have recently been applied to improve acquisition, measurement, and classification tasks in neonatal hip ultrasound. Objective: To systematically map and synthesise the literature on AI/ML applications for neonatal hip ultrasound, identifying algorithmic approaches, tasks, study characteristics, performance metrics, and knowledge gaps. Methods: A scoping review was conducted using the Arksey and O’Malley framework, refined by the Joanna Briggs Institute, and reported according to PRISMA‐ScR. The protocol was registered in PROSPERO (CRD420251150044). The protocol was initially registered as a systematic review and subsequently conducted as a scoping review; this methodological adaptation is acknowledged. PubMed/MEDLINE, Embase, Scopus, and IEEE Xplore were searched for English‐language studies from January 1, 2015, to September 10, 2025. Eligible studies evaluated AI/ML algorithms for neonatal hip ultrasound in infants ≤ 12 months. Results: From 192 records, 41 studies met inclusion criteria. Publications increased from 2020 onward, with China and Canada contributing over half. Most were retrospective, single‐centre developments using convolutional neural networks; a minority used YOLO detectors or transformer models. Tasks included landmark detection/segmentation (53.7%), automated α / β angle estimation (26.8%), classification (19.5%), and scan quality assessment (≈10%). Because some studies addressed multiple analytic tasks, these categories were not mutually exclusive and percentages therefore exceed 100%. Internal performance was high (ICC up to 0.94, Dice > 0.90, AUC ≥ 0.95), but external validation was rare (≈5%). Conclusion: AI/ML has been applied to neonatal hip ultrasound primarily for landmark detection, angle estimation, classification, and scan‐quality assessment. Reported internal performance is often high; however, clinically relevant diagnostic accuracy studies remain limited, external validation is rare, and most evidence derives from single‐centre datasets. These limitations currently constrain clinical generalizability.
- Open Access
- 22 April 2026
- Published by Queen's University Library in POCUS Journal
- Vol. 11 (01) , 110-120
Cranial POCUS in Neonates and Infants: Structured Evidence Synthesis and Proposal of the KORE Brain POCUS Protocol
Background: Cranial point of care ultrasound (POCUS) is an emerging bedside tool for rapid evaluation of neurological emergencies in neonates and infants. Although widely used in neonatal intensive care, its application in emergency and critical care remains heterogeneous and lacks standardized protocols. Objective: To synthesize the current literature on cranial POCUS in neonates and infants and propose a structured clinical protocol (KORE Brain POCUS Protocol) to support early diagnosis and management in emergency and critical care settings. Methods: A structured search of PubMed, Scopus, Web of Science, and Cochrane Library (through August 2025) identified studies on cranial POCUS in neonatal and infant acute care. Eligible studies included original research, observational studies, case series, and narrative or systematic reviews. Two reviewers independently screened and extracted data on study characteristics, clinical context, and feasibility. Results: Nine studies met the inclusion criteria. Cranial POCUS was consistently reported as feasible for detecting intracranial hemorrhage (ICH), ventricular dilatation, sinovenous thrombosis, and posterior fossa lesions, and for assessing cerebral hemodynamics using transcranial Doppler. Based on converging findings, we developed the KORE Brain POCUS Protocol, a stepwise framework integrating standardized ultrasound windows and Doppler assessment for pediatric emergency and critical care. Conclusions: Cranial POCUS is a promising, rapid, noninvasive tool for the bedside evaluation of acute neurological conditions in neonates and infants. The proposed KORE Brain POCUS Protocol provides a structured approach to support early diagnosis and clinical decision-making. Prospective studies are needed to validate its diagnostic performance and clinical impact.
- 22 April 2026
- Published by Queen's University Library in POCUS Journal
- Vol. 11 (01) , 110-120
Open AccessCranial POCUS in Neonates and Infants: Structured Evidence Synthesis and Proposal of the KORE Brain POCUS Protocol
Background: Cranial point of care ultrasound (POCUS) is an emerging bedside tool for rapid evaluation of neurological emergencies in neonates and infants. Although widely used in neonatal intensive care, its application in emergency and critical care remains heterogeneous and lacks standardized protocols. Objective: To synthesize the current literature on cranial POCUS in neonates and infants and propose a structured clinical protocol (KORE Brain POCUS Protocol) to support early diagnosis and management in emergency and critical care settings. Methods: A structured search of PubMed, Scopus, Web of Science, and Cochrane Library (through August 2025) identified studies on cranial POCUS in neonatal and infant acute care. Eligible studies included original research, observational studies, case series, and narrative or systematic reviews. Two reviewers independently screened and extracted data on study characteristics, clinical context, and feasibility. Results: Nine studies met the inclusion criteria. Cranial POCUS was consistently reported as feasible for detecting intracranial hemorrhage (ICH), ventricular dilatation, sinovenous thrombosis, and posterior fossa lesions, and for assessing cerebral hemodynamics using transcranial Doppler. Based on converging findings, we developed the KORE Brain POCUS Protocol, a stepwise framework integrating standardized ultrasound windows and Doppler assessment for pediatric emergency and critical care. Conclusions: Cranial POCUS is a promising, rapid, noninvasive tool for the bedside evaluation of acute neurological conditions in neonates and infants. The proposed KORE Brain POCUS Protocol provides a structured approach to support early diagnosis and clinical decision-making. Prospective studies are needed to validate its diagnostic performance and clinical impact.
- Open Access
- 17 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 3065
The Microbiota–Gut–Brain Axis Across the Lifespan: From Neurodevelopment to Neurodegeneration
The microbiota–gut–brain axis (MGBA) is a complex bidirectional communication network integrating neural, endocrine, immune, and metabolic pathways linking intestinal microbiota to central nervous system function. Increasing evidence indicates that microbiota-derived signals are critical regulators of neurodevelopment and may contribute to vulnerability to neurodegenerative disorders across the lifespan. In this narrative review, we synthesize experimental and clinical evidence to define the key biological mechanisms underlying microbiota–brain interactions. Converging data indicate that immune activation, barrier dysfunction, and microbial metabolites, particularly short-chain fatty acids and tryptophan-derived compounds, represent central mediators linking gut dysbiosis to neuroinflammatory and neurodegenerative processes. Early-life microbial perturbations, driven by factors such as antibiotic exposure, diet, and psychosocial stress, appear to induce long-term immunometabolic programming that may increase susceptibility to neurological disorders later in life. Clinical studies consistently associate dysbiosis with neurodevelopmental conditions and major neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease; however, causal relationships remain incompletely defined due to heterogeneity and the predominance of observational data. Overall, the available evidence supports a lifespan model in which microbiota-driven immune and metabolic dysregulation contributes to both early neurodevelopmental trajectories and late-life neurodegeneration. While microbiome-based biomarkers and therapeutic strategies show promise, their clinical translation requires validation in longitudinal and interventional studies.
- 17 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 3065
Open AccessThe Microbiota–Gut–Brain Axis Across the Lifespan: From Neurodevelopment to Neurodegeneration
The microbiota–gut–brain axis (MGBA) is a complex bidirectional communication network integrating neural, endocrine, immune, and metabolic pathways linking intestinal microbiota to central nervous system function. Increasing evidence indicates that microbiota-derived signals are critical regulators of neurodevelopment and may contribute to vulnerability to neurodegenerative disorders across the lifespan. In this narrative review, we synthesize experimental and clinical evidence to define the key biological mechanisms underlying microbiota–brain interactions. Converging data indicate that immune activation, barrier dysfunction, and microbial metabolites, particularly short-chain fatty acids and tryptophan-derived compounds, represent central mediators linking gut dysbiosis to neuroinflammatory and neurodegenerative processes. Early-life microbial perturbations, driven by factors such as antibiotic exposure, diet, and psychosocial stress, appear to induce long-term immunometabolic programming that may increase susceptibility to neurological disorders later in life. Clinical studies consistently associate dysbiosis with neurodevelopmental conditions and major neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease; however, causal relationships remain incompletely defined due to heterogeneity and the predominance of observational data. Overall, the available evidence supports a lifespan model in which microbiota-driven immune and metabolic dysregulation contributes to both early neurodevelopmental trajectories and late-life neurodegeneration. While microbiome-based biomarkers and therapeutic strategies show promise, their clinical translation requires validation in longitudinal and interventional studies.
- Open Access
Early-Life Microbiota Modulation and Neurodevelopment in Infants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Changes in microbial composition during early infancy by various factors (mode of delivery, nutritional practices, antibiotic usage, and environmental influences) have been correlated with observable variances in cognitive abilities, temperament, stress response, and the predisposition to neurodevelopmental disorders. Consequently, microbiota-targeted interventions such as probiotics, prebiotics, and synbiotics are being explored as avenues to enrich beneficial microbial taxa, enhance short-chain fatty acid production, fortify mucosal immunity, and mitigate inflammatory responses during these critical periods. Preclinical research, primarily in experimental animal models, has demonstrated a causal link between microbiota composition and developmental processes such as myelination, synaptic plasticity, and socio-emotional behaviors, whereas human evidence remains largely associative and heterogeneous. A notable gap exists in the current literature, which typically centers on gastrointestinal, psychiatric, or preterm outcomes, without a focused investigation into neurodevelopmental assessments within the first three years. To bridge this gap, we conducted a systematic review and meta-analysis of randomized controlled trials assessing the impact of probiotics, prebiotics, and synbiotics on neurodevelopment and behavior in infants aged 0–36 months. Our primary objective was to establish whether microbiota-targeted strategies confer discernible neurodevelopmental benefits, alongside elucidating the mechanisms underpinning the relationship between microbial modulation and early brain development.
Open AccessEarly-Life Microbiota Modulation and Neurodevelopment in Infants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Changes in microbial composition during early infancy by various factors (mode of delivery, nutritional practices, antibiotic usage, and environmental influences) have been correlated with observable variances in cognitive abilities, temperament, stress response, and the predisposition to neurodevelopmental disorders. Consequently, microbiota-targeted interventions such as probiotics, prebiotics, and synbiotics are being explored as avenues to enrich beneficial microbial taxa, enhance short-chain fatty acid production, fortify mucosal immunity, and mitigate inflammatory responses during these critical periods. Preclinical research, primarily in experimental animal models, has demonstrated a causal link between microbiota composition and developmental processes such as myelination, synaptic plasticity, and socio-emotional behaviors, whereas human evidence remains largely associative and heterogeneous. A notable gap exists in the current literature, which typically centers on gastrointestinal, psychiatric, or preterm outcomes, without a focused investigation into neurodevelopmental assessments within the first three years. To bridge this gap, we conducted a systematic review and meta-analysis of randomized controlled trials assessing the impact of probiotics, prebiotics, and synbiotics on neurodevelopment and behavior in infants aged 0–36 months. Our primary objective was to establish whether microbiota-targeted strategies confer discernible neurodevelopmental benefits, alongside elucidating the mechanisms underpinning the relationship between microbial modulation and early brain development.
- Open Access
- 14 March 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 255, 108775
Relationships between lung ultrasound, chest CT, and echocardiographic findings in children with bronchopulmonary dysplasia: A multimodal imaging study
- 14 March 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 255, 108775
Open AccessRelationships between lung ultrasound, chest CT, and echocardiographic findings in children with bronchopulmonary dysplasia: A multimodal imaging study
- 28 January 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (4) , 542-550
Lung Ultrasound in Bronchopulmonary Dysplasia: A Comparative Diagnostic Study With CT , Chest X‐Ray and Pulmonary Function Tests
Background: Chest x‐ray (CXR) and computed tomography (CT) are commonly used for diagnosing bronchopulmonary dysplasia (BPD), though each modality has limitations. CXR has low sensitivity for early parenchymal changes, while CT involves radiation exposure. Lung ultrasound (LUS) has emerged as a promising, radiation‐free alternative. Objective: To assess the diagnostic accuracy of LUS in BPD compared to CT and CXR, and to evaluate correlations between LUS scores and pulmonary function parameters, including spirometry, interrupter resistance technique (RINT), and nocturnal respiratory monitoring (pulse oximetry, polygraphy). Methods: This was a retrospective, single‐center, cross‐sectional study conducted over 12 months at San Marco University Hospital (Catania, Italy). Sixty paediatric patients with BPD underwent LUS, CXR and high‐resolution CT (HRCT). Pulmonary function tests (spirometry, RINT) and nocturnal monitoring were performed when feasible. Diagnostic performance of LUS was evaluated using receiver operating characteristic (ROC) curves and intraclass correlation coefficient (ICC). Correlations with functional parameters were analysed using Spearman's coefficient. Results: LUS showed good concordance with CT (ICC = 0.78; 95% CI: 0.72–0.85) and higher diagnostic accuracy than CXR (AUC = 0.87 vs. 0.67). LUS was particularly sensitive in detecting moderate parenchymal abnormalities. LUS scores correlated significantly with airway resistance ( r = 0.85), FEV 1 ( r = −0.65), and oxygen desaturation index ( r = 0.50). Conclusion: In this study, LUS demonstrated good concordance with CT and outperformed CXR. Its correlation with pulmonary function parameters suggests potential utility in the assessment and monitoring of BPD. Further studies with larger cohorts are needed to validate these findings.
- 28 January 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (4) , 542-550
Lung Ultrasound in Bronchopulmonary Dysplasia: A Comparative Diagnostic Study With CT , Chest X‐Ray and Pulmonary Function Tests
Background: Chest x‐ray (CXR) and computed tomography (CT) are commonly used for diagnosing bronchopulmonary dysplasia (BPD), though each modality has limitations. CXR has low sensitivity for early parenchymal changes, while CT involves radiation exposure. Lung ultrasound (LUS) has emerged as a promising, radiation‐free alternative. Objective: To assess the diagnostic accuracy of LUS in BPD compared to CT and CXR, and to evaluate correlations between LUS scores and pulmonary function parameters, including spirometry, interrupter resistance technique (RINT), and nocturnal respiratory monitoring (pulse oximetry, polygraphy). Methods: This was a retrospective, single‐center, cross‐sectional study conducted over 12 months at San Marco University Hospital (Catania, Italy). Sixty paediatric patients with BPD underwent LUS, CXR and high‐resolution CT (HRCT). Pulmonary function tests (spirometry, RINT) and nocturnal monitoring were performed when feasible. Diagnostic performance of LUS was evaluated using receiver operating characteristic (ROC) curves and intraclass correlation coefficient (ICC). Correlations with functional parameters were analysed using Spearman's coefficient. Results: LUS showed good concordance with CT (ICC = 0.78; 95% CI: 0.72–0.85) and higher diagnostic accuracy than CXR (AUC = 0.87 vs. 0.67). LUS was particularly sensitive in detecting moderate parenchymal abnormalities. LUS scores correlated significantly with airway resistance ( r = 0.85), FEV 1 ( r = −0.65), and oxygen desaturation index ( r = 0.50). Conclusion: In this study, LUS demonstrated good concordance with CT and outperformed CXR. Its correlation with pulmonary function parameters suggests potential utility in the assessment and monitoring of BPD. Further studies with larger cohorts are needed to validate these findings.